Skip to main content
PMC home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1981 Feb;134(2):109–127.

Disorders of Platelet Function

Mechanisms, Diagnosis and Management

Lothar B Huebsch 1, Laurence A Harker 1
PMCID: PMC1272531  PMID: 7013276

Abstract

Platelets play an important role in hemostasis, and alterations in platelet function may be the cause of abnormal bleeding in a wide variety of congenital and acquired clinical disorders. Platelet dysfunction may be classified as disorders of (1) substrate connective tissue, (2) adhesion, (3) aggregation and (4) platelet-release reaction. The congenital defects of platelet function, although uncommon, have provided important insights into platelet physiology and pathophysiology and, as a group, are less common, better characterized and more readily classified than the acquired defects.

The severity of bleeding resulting from platelet dysfunction varies greatly and is substantially increased when another defect of hemostasis coexists. A disorder of platelet function is suspected on the basis of the history and physical examination and is confirmed by the finding of a prolonged bleeding time in the presence of an adequate number of platelets. A specific diagnosis often requires measurements of the factor VIII and von Willebrand factor complex and other tests of platelet function. Some of these tests may be available only in specialized laboratories.

Therapy for bleeding episodes resulting from platelet dysfunction is directed at (1) removing or treating the underlying cause of the platelet disorder; (2) replacing the missing plasma cofactors needed to support normal platelet function (such as by the transfusion of cryoprecipitate in patients with von Willebrand disease, and (3) transfusing functional platelets in the form of platelet concentrates in patients with disorders of intrinsic platelet dysfunction.

Full text

PDF
127

Images in this article

110Figure 1.
on p.110
111Figure 2.
on p.111
124Figure 3.
on p.124

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ali M., McDonald J. W. Effects of sulfinpyrazone on platelet prostaglandin synthesis and platelet release of serotonin. J Lab Clin Med. 1977 Apr;89(4):868–875. [PubMed] [Google Scholar]
  2. Babcock R. B., Dumper C. W., Scharfman W. B. Heparin-induced immune thrombocytopenia. N Engl J Med. 1976 Jul 29;295(5):237–241. doi: 10.1056/NEJM197607292950501. [DOI] [PubMed] [Google Scholar]
  3. Baumgartner H. R., Muggli R., Tschopp T. B., Turitto V. T. Platelet adhesion, release and aggregation in flowing blood: effects of surface properties and platelet function. Thromb Haemost. 1976 Feb 29;35(1):124–138. [PubMed] [Google Scholar]
  4. Bell R. L., Majerus P. W. Thrombin-induced hydrolysis of phosphatidylinositol in human platelets. J Biol Chem. 1980 Mar 10;255(5):1790–1792. [PubMed] [Google Scholar]
  5. Bick R. L. Alterations of hemostasis associated with cardiopulmonary bypass: pathophysiology, prevention, diagnosis, and management. Semin Thromb Hemost. 1976 Oct;3(2):59–82. doi: 10.1055/s-0028-1086129. [DOI] [PubMed] [Google Scholar]
  6. Boughton B. J., Corbett W. E., Ginsburg A. D. Myeloproliferative disorders: a paradox of in-vivo and in-vitro platelet function. J Clin Pathol. 1977 Mar;30(3):228–234. doi: 10.1136/jcp.30.3.228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Brown C. H., 3rd, Natelson E. A., Bradshaw W., Williams T. W., Jr, Alfrey C. P., Jr The hemostatic defect produced by carbenicillin. N Engl J Med. 1974 Aug 8;291(6):265–270. doi: 10.1056/NEJM197408082910601. [DOI] [PubMed] [Google Scholar]
  8. Brownstein M. H., Helwig E. B. The cutaneous amyloidoses. II. Systemic forms. Arch Dermatol. 1970 Jul;102(1):20–28. [PubMed] [Google Scholar]
  9. Burch J. W., Majerus P. W. The role of prostaglandins in platelet function. Semin Hematol. 1979 Jul;16(3):196–207. [PubMed] [Google Scholar]
  10. Burch J. W., Stanford N., Majerus P. W. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest. 1978 Feb;61(2):314–319. doi: 10.1172/JCI108941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cardamone J. M., Edson J. R., McArthur J. R., Jacob H. S. Abnormalities of platelet function in the myeloproliferative disorders. JAMA. 1972 Jul 17;221(3):270–273. [PubMed] [Google Scholar]
  12. Castaldi P. A., Rozenberg M. C., Stewart J. H. The bleeding disorder of uraemia. A qualitative platelet defect. Lancet. 1966 Jul 9;2(7454):66–69. doi: 10.1016/s0140-6736(66)91802-2. [DOI] [PubMed] [Google Scholar]
  13. Clagett G. P., Salzman E. W. Prevention of venous thromboembolism. Prog Cardiovasc Dis. 1975 Mar-Apr;17(5):345–366. doi: 10.1016/s0033-0620(75)80011-9. [DOI] [PubMed] [Google Scholar]
  14. Clancy R., Jenkins E., Firkin B. Qualitative platelet abnormalities in idiopathic thrombocytopenic purpura. N Engl J Med. 1972 Mar 23;286(12):622–626. doi: 10.1056/NEJM197203232861202. [DOI] [PubMed] [Google Scholar]
  15. Coller B. S. Interaction of normal, thrombasthenic, and Bernard-Soulier platelets with immobilized fibrinogen: defective platelet-fibrinogen interaction in thrombasthenia. Blood. 1980 Feb;55(2):169–178. [PubMed] [Google Scholar]
  16. Cowan D. H. Effect of alcoholism on hemostasis. Semin Hematol. 1980 Apr;17(2):137–147. [PubMed] [Google Scholar]
  17. Cowan D. H., Graham R. C., Jr, Baunach D. The platelet defect in leukemia. Platelet ultrastructure, adenine nucleotide metabolism, and the release reaction. J Clin Invest. 1975 Jul;56(1):188–200. doi: 10.1172/JCI108067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Crawford N., Taylor D. G. Biochemical aspects of platelet behaviour associated with surface membrane reactivity. Br Med Bull. 1977 Sep;33(3):199–206. doi: 10.1093/oxfordjournals.bmb.a071436. [DOI] [PubMed] [Google Scholar]
  19. Czapek E. E., Deykin D., Salzman E., Lian E. C., Hellerstein L. J., Rosoff C. B. Intermediate syndrome of platelet dysfunction. Blood. 1978 Jul;52(1):103–113. [PubMed] [Google Scholar]
  20. Dyerberg J., Bang H. O. Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet. 1979 Sep 1;2(8140):433–435. doi: 10.1016/s0140-6736(79)91490-9. [DOI] [PubMed] [Google Scholar]
  21. Gerrard J. M., Phillips D. R., Rao G. H., Plow E. F., Walz D. A., Ross R., Harker L. A., White J. G. Biochemical studies of two patients with the gray platelet syndrome. Selective deficiency of platelet alpha granules. J Clin Invest. 1980 Jul;66(1):102–109. doi: 10.1172/JCI109823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Gerrard J. M., Stoddard S. F., Shapiro R. S., Coccia P. F., Ramsay N. K., Nesbit M. E., Rao G. H., Krivit W., White J. G. Platelet storage pool deficiency and prostaglandin synthesis in chronic granulocytic leukaemia. Br J Haematol. 1978 Dec;40(4):597–607. doi: 10.1111/j.1365-2141.1978.tb05836.x. [DOI] [PubMed] [Google Scholar]
  23. Gerrard J. M., White J. G. Prostaglandins and thromboxanes: "middlemen" modulating platelet function in hemostasis and thrombosis. Prog Hemost Thromb. 1978;4:87–125. [PubMed] [Google Scholar]
  24. Glenner G. G. Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N Engl J Med. 1980 Jun 5;302(23):1283–1292. doi: 10.1056/NEJM198006053022305. [DOI] [PubMed] [Google Scholar]
  25. Gralnick H. R., Sultan Y., Coller B. S. Von Willebrand's disease: combined qualitative and quantitative abnormalities. N Engl J Med. 1977 May 5;296(18):1024–1030. doi: 10.1056/NEJM197705052961802. [DOI] [PubMed] [Google Scholar]
  26. Greipp P. R., Kyle R. A., Bowie E. J. Factor X deficiency in primary amyloidosis: resolution after splenectomy. N Engl J Med. 1979 Nov 8;301(19):1050–1051. doi: 10.1056/NEJM197911083011907. [DOI] [PubMed] [Google Scholar]
  27. Handin R. I., Martin V., Moloney W. C. Antibody-induced von Willebrand's disease: a newly defined inhibitor syndrome. Blood. 1976 Sep;48(3):393–405. [PubMed] [Google Scholar]
  28. Hardisty R. M. Disorders of platelet function. Br Med Bull. 1977 Sep;33(3):207–212. doi: 10.1093/oxfordjournals.bmb.a071437. [DOI] [PubMed] [Google Scholar]
  29. Harker L. A., Hanson S. R. Experimental arterial thromboembolism in baboons. Mechanism, quantitation, and pharmacologic prevention. J Clin Invest. 1979 Aug;64(2):559–560. doi: 10.1172/JCI109494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Harker L. A., Malpass T. W., Branson H. E., Hessel E. A., 2nd, Slichter S. J. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood. 1980 Nov;56(5):824–834. [PubMed] [Google Scholar]
  31. Harker L. A., Ross R. Pathogenesis of arterial vascular disease. Semin Thromb Hemost. 1979 Spring;5(4):274–292. doi: 10.1055/s-0028-1087159. [DOI] [PubMed] [Google Scholar]
  32. Harker L. A., Slichter S. J. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med. 1972 Jul 27;287(4):155–159. doi: 10.1056/NEJM197207272870401. [DOI] [PubMed] [Google Scholar]
  33. Haut M. J., Cowan D. H. The effect of ethanol on hemostatic properties of human blood platelets. Am J Med. 1974 Jan;56(1):22–33. doi: 10.1016/0002-9343(74)90747-5. [DOI] [PubMed] [Google Scholar]
  34. Holmsen H., Weiss H. J. Further evidence for a deficient storage pool of adenine nucleotides in platelets from some patients with thrombocytopathia--"storage pool disease". Blood. 1972 Feb;39(2):197–209. [PubMed] [Google Scholar]
  35. Holmsen H., Weiss H. J. Secretable storage pools in platelets. Annu Rev Med. 1979;30:119–134. doi: 10.1146/annurev.me.30.020179.001003. [DOI] [PubMed] [Google Scholar]
  36. Horowitz H. I., Stein I. M., Cohen B. D., White J. G. Further studies on the platelet-inhibitory effect of guanidinosuccinic acid and its role in uremic bleeding. Am J Med. 1970 Sep;49(3):336–345. doi: 10.1016/s0002-9343(70)80025-0. [DOI] [PubMed] [Google Scholar]
  37. Hoyer L. W. Von Willebrand's disease. Prog Hemost Thromb. 1976;3:231–287. [PubMed] [Google Scholar]
  38. Ingram G. I. Investigation of a long-standing bleeding tendency. Br Med Bull. 1977 Sep;33(3):261–264. doi: 10.1093/oxfordjournals.bmb.a071445. [DOI] [PubMed] [Google Scholar]
  39. Ingram G. I., Prentice C. R., Forbes C. D., Leslie J. Low factor-VIII-like antigen in acquired Von Willebrand's syndrome and response to treatment. Br J Haematol. 1973 Jul;25(1):137–140. doi: 10.1111/j.1365-2141.1973.tb01723.x. [DOI] [PubMed] [Google Scholar]
  40. Joist J. H., Cowan J. F., Zimmerman T. S. Acquired von Willebrand's disease. Evidence for a quantitative and qualitative factor VIII disorder. N Engl J Med. 1978 May 4;298(18):988–991. doi: 10.1056/NEJM197805042981802. [DOI] [PubMed] [Google Scholar]
  41. Kaplan K. L., Broekman M. J., Chernoff A., Lesznik G. R., Drillings M. Platelet alpha-granule proteins: studies on release and subcellular localization. Blood. 1979 Apr;53(4):604–618. [PubMed] [Google Scholar]
  42. Karpatkin S., Lackner H. L. Association of antiplatelet antibody with functional platelet disorders. Autoimmune thrombocytopenic purpura, systemic lupus erythematosus and thrombopathia. Am J Med. 1975 Nov;59(5):599–604. doi: 10.1016/0002-9343(75)90221-1. [DOI] [PubMed] [Google Scholar]
  43. Kaywin P., McDonough M., Insel P. A., Shattil S. J. Platelet function in essential thrombocythemia. Decreased epinephrine responsiveness associated with a deficiency of platelet alpha-adrenergic receptors. N Engl J Med. 1978 Sep 7;299(10):505–509. doi: 10.1056/NEJM197809072991002. [DOI] [PubMed] [Google Scholar]
  44. Kinlough-Rathbone R. L., Packham M. A., Reimers H. J., Cazenave J. P., Mustard J. F. Mechanisms of platelet shape change, aggregation, and release induced by collagen, thrombin, or A23,187. J Lab Clin Med. 1977 Oct;90(4):707–719. [PubMed] [Google Scholar]
  45. Lagarde M., Byron P. A., Vargaftig B. B., Dechavanne M. Impairment of platelet thromboxane A2 generation and of the platelet release reaction in two patients with congenital deficiency of platelet cyclo-oxygenase. Br J Haematol. 1978 Feb;38(2):251–266. doi: 10.1111/j.1365-2141.1978.tb01041.x. [DOI] [PubMed] [Google Scholar]
  46. Lisiewicz J. Mechanisms of hemorrhage in leukemias. Semin Thromb Hemost. 1978 Winter;4(3):241–267. doi: 10.1055/s-0028-1087134. [DOI] [PubMed] [Google Scholar]
  47. Malmsten C., Hamberg M., Svensson J., Samuelsson B. Physiological role of an endoperoxide in human platelets: hemostatic defect due to platelet cyclo-oxygenase deficiency. Proc Natl Acad Sci U S A. 1975 Apr;72(4):1446–1450. doi: 10.1073/pnas.72.4.1446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Malpass T. W., Harker L. A. Acquired disorders of platelet function. Semin Hematol. 1980 Oct;17(4):242–258. [PubMed] [Google Scholar]
  49. Mestel F., Oetliker O., Beck E., Felix R., Imbach P., Wagner H. P. Severe bleeding associated with defective thromboxane synthetase. Lancet. 1980 Jan 19;1(8160):157–157. doi: 10.1016/s0140-6736(80)90642-x. [DOI] [PubMed] [Google Scholar]
  50. Meyer D., Frommel D., Larrieu M. J., Zimmerman T. S. Selective absence of large forms of factor VIII/von Willebrand factor in acquired von Willebrand's syndrome. Response to transfusion. Blood. 1979 Sep;54(3):600–606. [PubMed] [Google Scholar]
  51. Michel H., Caen J. P., Born G. V., Miller R., D'Auriac G. A., Meyer P. Relation between the inhibition of aggregation and the concentration of cAMP in human and rat platelets. Br J Haematol. 1976 May;33(1):27–38. doi: 10.1111/j.1365-2141.1976.tb00969.x. [DOI] [PubMed] [Google Scholar]
  52. Mielke C. H., Jr, Kaneshiro M. M., Maher I. A., Weiner J. M., Rapaport S. I. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood. 1969 Aug;34(2):204–215. [PubMed] [Google Scholar]
  53. Miletich J. P., Kane W. H., Hofmann S. L., Stanford N., Majerus P. W. Deficiency of factor Xa-factor Va binding sites on the platelets of a patient with a bleeding disorder. Blood. 1979 Nov;54(5):1015–1022. [PubMed] [Google Scholar]
  54. Miller C. H., Graham J. B., Goldin L. R., Elston R. C. Genetics of classic von Willebrand's disease. I. Phenotypic variation within families. Blood. 1979 Jul;54(1):117–136. [PubMed] [Google Scholar]
  55. Mitchell J. R. Clinical events resulting from thrombus formation. Br Med Bull. 1978 May;34(2):103–106. doi: 10.1093/oxfordjournals.bmb.a071478. [DOI] [PubMed] [Google Scholar]
  56. Moncada S., Korbut R. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet. 1978 Jun 17;1(8077):1286–1289. doi: 10.1016/s0140-6736(78)91269-2. [DOI] [PubMed] [Google Scholar]
  57. Moncada S., Vane J. R. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med. 1979 May 17;300(20):1142–1147. doi: 10.1056/NEJM197905173002006. [DOI] [PubMed] [Google Scholar]
  58. Moncada S., Vane J. R. Mode of action of aspirin-like drugs. Adv Intern Med. 1979;24:1–22. [PubMed] [Google Scholar]
  59. Murphy S., Davis J. L., Walsh P. N., Gardner F. H. Template bleeding time and clinical hemorrhage in myeloproliferative disease. Arch Intern Med. 1978 Aug;138(8):1251–1253. [PubMed] [Google Scholar]
  60. Mustard J. F., Packham M. A. Normal and abnormal haemostasis. Br Med Bull. 1977 Sep;33(3):187–192. doi: 10.1093/oxfordjournals.bmb.a071434. [DOI] [PubMed] [Google Scholar]
  61. Nilsson I. M., Bergentz S. E., Larsson S. A. Surgery in von Willebrand's disease. Ann Surg. 1979 Dec;190(6):746–752. doi: 10.1097/00000658-197912000-00014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Nurden A. T., Caen J. P. The different glycoprotein abnormalities in thrombasthenic and Bernard-Soulier platelets. Semin Hematol. 1979 Jul;16(3):234–250. [PubMed] [Google Scholar]
  63. Orloff K. G., Michaeli D. Inhibition of fibrin-platelet interactions by fibrinogen-degradation fragment D. Am J Physiol. 1977 Aug;233(2):H305–H311. doi: 10.1152/ajpheart.1977.233.2.H305. [DOI] [PubMed] [Google Scholar]
  64. Packham M. A., Mustard J. F. Clinical pharmacology of platelets. Blood. 1977 Oct;50(4):555–573. [PubMed] [Google Scholar]
  65. Perkins H. A., MacKenzie M. R., Fudenberg H. H. Hemostatic defects in dysproteinemias. Blood. 1970 May;35(5):695–707. [PubMed] [Google Scholar]
  66. Raccuglia G. Gray platelet syndrome. A variety of qualitative platelet disorder. Am J Med. 1971 Dec;51(6):818–828. doi: 10.1016/0002-9343(71)90311-1. [DOI] [PubMed] [Google Scholar]
  67. Rosenberg R. D. Biologic actions of heparin. Semin Hematol. 1977 Oct;14(4):427–440. [PubMed] [Google Scholar]
  68. Rossi E. C., Levin N. W. Inhibition of primary ADP-induced platelet aggregation in normal subjects after administration of nitrofurantoin (furadantin). J Clin Invest. 1973 Oct;52(10):2457–2467. doi: 10.1172/JCI107437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Roth G. J., Stanford N., Majerus P. W. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975 Aug;72(8):3073–3076. doi: 10.1073/pnas.72.8.3073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Ruggeri Z. M., Pareti F. I., Mannucci P. M., Ciavarella N., Zimmerman T. S. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med. 1980 May 8;302(19):1047–1051. doi: 10.1056/NEJM198005083021902. [DOI] [PubMed] [Google Scholar]
  71. Russell N. H., Keenan J. P., Bellingham A. J. Thrombocytopathy in preleukaemia: association with a defect of thromboxane A2 activity. Br J Haematol. 1979 Mar;41(3):417–425. doi: 10.1111/j.1365-2141.1979.tb05876.x. [DOI] [PubMed] [Google Scholar]
  72. Russell N. H., Keenan J. P., Frais M. A. Thrombocytopathy associated with autoimmune haemolytic anaemia. Br Med J. 1978 Aug 26;2(6137):604–604. doi: 10.1136/bmj.2.6137.604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. SALZMAN E. W. MEASUREMENT OF PLATELET ADHESIVENESS. A SIMPLE IN VITRO TECHNIQUE DEMONSTRATING AN ABNORMALITY IN VON WILLEBRAND'S DISEASE. J Lab Clin Med. 1963 Nov;62:724–735. [PubMed] [Google Scholar]
  74. Sakariassen K. S., Bolhuis P. A., Sixma J. J. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor bound to the subendothelium. Nature. 1979 Jun 14;279(5714):636–638. doi: 10.1038/279636a0. [DOI] [PubMed] [Google Scholar]
  75. Salzman E. W., Rosenberg R. D., Smith M. H., Lindon J. N., Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest. 1980 Jan;65(1):64–73. doi: 10.1172/JCI109661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Santoro S. A., Cunningham L. W. Fibronectin and the multiple interaction model for platelet-collagen adhesion. Proc Natl Acad Sci U S A. 1979 Jun;76(6):2644–2648. doi: 10.1073/pnas.76.6.2644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Schick P. K. The role of platelet membrane lipids in platelet hemostatic activities. Semin Hematol. 1979 Jul;16(3):221–233. [PubMed] [Google Scholar]
  78. Sharp A. A. Diagnosis and management of disseminated intravascular coagulation. Br Med Bull. 1977 Sep;33(3):265–272. doi: 10.1093/oxfordjournals.bmb.a071446. [DOI] [PubMed] [Google Scholar]
  79. Shattil S. J., Bennett J. S., McDonough M., Turnbull J. Carbenicillin and penicillin G inhibit platelet function in vitro by impairing the interaction of agonists with the platelet surface. J Clin Invest. 1980 Feb;65(2):329–337. doi: 10.1172/JCI109676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Siess W., Roth P., Scherer B., Kurzmann I., Böhlig B., Weber P. C. Platelet-membrane fatty acids, platelet aggregation, and thromboxane formation during a mackerel diet. Lancet. 1980 Mar 1;1(8166):441–444. doi: 10.1016/s0140-6736(80)90995-2. [DOI] [PubMed] [Google Scholar]
  81. Slichter S. J. Controversies in platelet transfusion therapy. Annu Rev Med. 1980;31:509–540. doi: 10.1146/annurev.me.31.020180.002453. [DOI] [PubMed] [Google Scholar]
  82. Slichter S. J., Harker L. A. Thrombocytopenia: mechanisms and management of defects in platelet production. Clin Haematol. 1978 Oct;7(3):523–539. [PubMed] [Google Scholar]
  83. Steiner R. W., Coggins C., Carvalho A. C. Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Hematol. 1979;7(2):107–117. doi: 10.1002/ajh.2830070203. [DOI] [PubMed] [Google Scholar]
  84. Sullivan J. M., Harken D. E., Gorlin R. Pharmacologic control of thromboembolic complications of cardiac-valve replacement. N Engl J Med. 1971 Jun 24;284(25):1391–1394. doi: 10.1056/NEJM197106242842501. [DOI] [PubMed] [Google Scholar]
  85. Tschopp T. B., Weiss H. J., Baumgartner H. R. Decreased adhesion of platelets to subendothelium in von Willebrand's disease. J Lab Clin Med. 1974 Feb;83(2):296–300. [PubMed] [Google Scholar]
  86. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232–235. doi: 10.1038/newbio231232a0. [DOI] [PubMed] [Google Scholar]
  87. WEARY P. E., WHEELER C. E., CAWLEY E. P. Adult scurvy. Report of a case. Arch Dermatol. 1961 Apr;83:657–659. doi: 10.1001/archderm.1961.01580100121017. [DOI] [PubMed] [Google Scholar]
  88. Wautier J. L., Caen J. P. Pharmacology of platelet-suppressive agents. Semin Thromb Hemost. 1979 Spring;5(4):293–315. doi: 10.1055/s-0028-1087160. [DOI] [PubMed] [Google Scholar]
  89. Weiss H. J., Ames R. P. Ultrastructural findings in storage pool disease and aspirin-like defects of platelets. Am J Pathol. 1973 Jun;71(3):447–466. [PMC free article] [PubMed] [Google Scholar]
  90. Weiss H. J., Baumgartner H. R., Tschopp T. B., Turitto V. T., Cohen D. Correction by factor VIII of the impaired platelet adhesion to subendothelium in von Willebrand disease. Blood. 1978 Feb;51(2):267–279. [PubMed] [Google Scholar]
  91. Weiss H. J. Congenital disorders of platelet function. Semin Hematol. 1980 Oct;17(4):228–241. [PubMed] [Google Scholar]
  92. Weiss H. J., Lages B. A. Possible congenital defect in platelet thromboxane synthetase. Lancet. 1977 Apr 2;1(8014):760–761. doi: 10.1016/s0140-6736(77)92213-9. [DOI] [PubMed] [Google Scholar]
  93. Weiss H. J. Platelet physiology and abnormalities of platelet function (second of two parts). N Engl J Med. 1975 Sep 18;293(12):580–588. doi: 10.1056/NEJM197509182931204. [DOI] [PubMed] [Google Scholar]
  94. Weiss H. J., Rogers J. Fibrinogen and platelets in the primary arrest of bleeding. Studies in two patients with congenital afibrinogenemia. N Engl J Med. 1971 Aug 12;285(7):369–374. doi: 10.1056/NEJM197108122850703. [DOI] [PubMed] [Google Scholar]
  95. Weiss H. J. The effect of clinical dextran on platelet aggregation, adhesion, and ADP release in man: in vivo and in vitro studies. J Lab Clin Med. 1967 Jan;69(1):37–46. [PubMed] [Google Scholar]
  96. Weiss H. J., Tschopp T. B., Baumgartner H. R., Sussman I. I., Johnson M. M., Egan J. J. Decreased adhesion of giant (Bernard-Soulier) platelets to subendothelium. Further implications on the role of the von Willebrand factor in hemostasis. Am J Med. 1974 Dec;57(6):920–925. doi: 10.1016/0002-9343(74)90170-3. [DOI] [PubMed] [Google Scholar]
  97. Weiss H. J., Vicic W. J., Lages B. A., Rogers J. Isolated deficiency of platelet procoagulant activity. Am J Med. 1979 Aug;67(2):206–213. doi: 10.1016/0002-9343(79)90392-9. [DOI] [PubMed] [Google Scholar]
  98. Weiss H. J., Witte L. D., Kaplan K. L., Lages B. A., Chernoff A., Nossel H. L., Goodman D. S., Baumgartner H. R. Heterogeneity in storage pool deficiency: studies on granule-bound substances in 18 patients including variants deficient in alpha-granules, platelet factor 4, beta-thromboglobulin, and platelet-derived growth factor. Blood. 1979 Dec;54(6):1296–1319. [PubMed] [Google Scholar]
  99. Zahavi J. Editorial: Acquired "storage pool disease" of platelets. Thromb Haemost. 1976 Jun 30;35(3):501–507. [PubMed] [Google Scholar]
  100. Zimmerman T. S., Abildgaard C. F., Meyer D. The factor VIII abnormality in severe von Willebrand's disease. N Engl J Med. 1979 Dec 13;301(24):1307–1310. doi: 10.1056/NEJM197912133012402. [DOI] [PubMed] [Google Scholar]
  101. Zucker M. B. The functioning of blood platelets. Sci Am. 1980 Jun;242(6):86–103. doi: 10.1038/scientificamerican0680-86. [DOI] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES